Caelyx

Monotherapy for metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum-based chemotherapy regimen. In combination w/ bortezomib for progressive multiple myeloma in patients who have received at least 1 prior therapy & have not previously received bortezomib & have already undergone or are unstable for bone marrow transplant. AIDS-related Kaposi's sarcoma (KS) in patients w/ low CD4 counts (<200 CD4 lymphocytes/mm³) & extensive mucocutaneous or visceral disease. 1st-line systemic or 2nd-line chemotherapy in AIDS-KS patients w/ disease that has progressed w/ or in those intolerant to, prior combination systemic chemotherapy comprising at least 2 of the following agents: Vinca alkaloid, bleomycin & standard doxorubicin (or other anthracyclines).

Breast/ovarian cancer 50 mg/m² IV once every 4 wk for as long as the disease does not progress & the patient continues to tolerate treatment. Multiple myeloma 30 mg/m² on day 4 of bortezomib 3-wk regimen as 1-hr infusion immediately after bortezomib infusion. Bortezomib regimen: 1.3 mg/m² on days 1, 4, 8 & 11 every 3 wk. AIDS-KS patient 20 mg/m² IV every 2-3 wk. Treatment duration: 2-3 mth; continue as needed. Hepatic impairment: Bilirubin level >3 mg/dL Reduce 1st dose by 50%, 1.2-3 mg/dL Reduce 1st dose by 25%. If patient tolerates 1st dose w/ no increase in serum bilirubin or liver enzymes, cycle 2 dose may be increased to next dose level.

Hypersensitivity. AIDS-KS that may be effectively treated w/ local therapy or systemic α-interferon. Pregnancy & lactation.

Cytotoxic Chemotherapy

L01DB01 - doxorubicin ; Belongs to the class of cytotoxic antibiotics, anthracyclines and related substances. Used in the treatment of cancer.

POM